7 in 10 Metastatic Breast Cancer Patients Benefit from LiPlaCis, Early Trial Data Shows

7 in 10 Metastatic Breast Cancer Patients Benefit from LiPlaCis, Early Trial Data Shows
A targeted liposomal formulation of the chemotherapy treatment cisplatin, called LiPlaCis, induced clinical benefit in 70 percent of breast cancer patients included in a Phase 1/2 trial. The clinical response, however, was 100 percent among patients identified as most susceptible to treatment, using the Medical Prognosis Institute's DRP companion diagnostic tool. The diagnostic was developed to identify patients who benefit and who do not benefit from a specific cancer treatment. "It is very encouraging that in this prospective study the DRP with statistical significance can identify responding and non-responding patients," Steen Knudsen, CSO and founder of Medical Prognosis Institute (MPI), said in a press release. Cisplatin, one of the most active chemotherapy drugs available, is used to treat a number of cancers, including breast cancer. But its current formulation, marketed as Platinol, is only effective in 10 percent of patients and shows significant toxicity. To reduce the toxicity of cisplatin, Oncology Venture, a spinoff of Denmark’s MPI, developed LiPlaCis — an encapsulated cisplatin formulation designed to del
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.